Currently out of the existing stock ratings of Dae Gon Ha, 45 are a BUY (71.43%), 18 are a HOLD (28.57%).

Dae Gon Ha

Work Performance Price Targets & Ratings Chart

Analyst Dae Gon Ha works at STIFEL with a stock forecast success ratio of 38.81% fulfilled within 103.14 days on average.

Dae Gon Ha’s has documented 122 price targets and ratings displayed on 22 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RARE, Ultragenyx at 16-Jan-2024.

Wall Street Analyst Dae Gon Ha

Analyst best performing recommendations are on EDIT (EDITAS MEDICINE).
The best stock recommendation documented was for EDIT (EDITAS MEDICINE) at 5/4/2022. The price target of $15 was fulfilled within 1 day with a profit of $0.81 (5.12%) receiving and performance score of 51.23.

Average potential price target upside

of $23.46 (100.28%) on RYTM (RHYTHM PHARMACEUTICALS).
of $19.44 (18.17%) on KRYS (KRYSTAL BIOTECH).
of $13.43 (83.57%) on KALV (KALVISTA PHARMACEUTICALS).

AVRO AVROBIO CCXI ChemoCentryx EDIT Editas Medicine FOLD Amicus Therapeutics FRLN Freeline Therapeutics Holdings Plc FULC Fulcrum Therapeutics AGTC Applied Genetic FIXX Homology Medicines ORTX Orchard Therapeutics PLC EQ Equillium PRQR ProQR Therapeutics BV RARE Ultragenyx RCKT Rocket Pharmaceuticals VERV Verve Therapeutics NTLA Intellia Therapeutics RYTM Rhythm Pharmaceuticals APLS Apellis Pharmaceuticals CRBP Corbus Pharmaceuticals KALV Kalvista Pharmaceuticals RETA Reata Pharmaceuticals SRZN Surrozen KRYS Krystal Biotech

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Uy Ear (MIZUHO)